GOLETA, Calif., Feb. 13, 2014 (GLOBE NEWSWIRE) -- Inogen, Inc. (Nasdaq:INGN) today announced the pricing of its initial public offering of 4,411,763 shares of its common stock at a price to the public of $16.00 per share. Inogen is offering 3,529,411 shares of common stock and certain selling stockholders are offering 882,352 shares of common stock. In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to 661,764 additional shares of common stock at the initial public offering price. The shares are expected to begin trading on The NASDAQ Global Select Market on February 14, 2014, under the symbol "INGN".
J.P. Morgan is acting as sole book-running manager for the offering, Leerink Partners is acting as lead manager, and William Blair and Stifel are acting as co-managers.
A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission. The offering is being made only by means of a prospectus. A copy of the final prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866) 803-9204.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
CONTACT: Investor Relations contact:
805-562-0500 ext: 7